Moving towards one global paediatric development plan
By Beatrix Friedeberg, Mette Due Theilade Thomsen, Annabel Bonsu and Evgenia Mengou2026-10-06T15:07:00
Abstract
Increasing alignment between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), alongside broader international regulatory developments, is reshaping expectations for paediatric evidence generation. It is also encouraging sponsors to take a more consistent approach to paediatric development planning.
This article reviews paediatric development requirements within a changing legislative landscape and proposes a model based on a single core scientific data package, supported by coordinated regional implementation.